Access Safety and Efficacy Post Endovascular Intervention
Status: | Completed |
---|---|
Conditions: | Peripheral Vascular Disease |
Therapuetic Areas: | Cardiology / Vascular Diseases |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 2/8/2015 |
Start Date: | December 2012 |
End Date: | June 2015 |
Contact: | Lilach Ofri |
Email: | lofri@Arstasis.com |
Phone: | 650-261-8043 |
AXERA Access Safety and Efficacy Post Endovascular INtervention
The goal of this study is to assess the safety and effectiveness of the AXERA Access System
in subjects undergoing Common Femoral Artery (CFA) access for Percutaneous Coronary
Intervention (PCI) and/or Peripheral Vascular Intervention (PVI) through a 5 French (F) or
6F introducer sheath.
in subjects undergoing Common Femoral Artery (CFA) access for Percutaneous Coronary
Intervention (PCI) and/or Peripheral Vascular Intervention (PVI) through a 5 French (F) or
6F introducer sheath.
Inclusion Criteria:
- Subject is 18 years of age or older.
- Subject is clinically indicated for a PCI or PVI involving access through a 5F or 6F
introducer sheath in the femoral artery.
- Subject is able to ambulate without assistance prior to the procedure and can be
expected to ambulate (20 feet) within 2 hours post procedure.
- Female subjects of child bearing potential must have a negative pregnancy test.
Exclusion Criteria:
- Subjects who are pregnant or lactating.
- Subject has a pre-existing severe non-cardiac systemic disease/illness or another
reason that results in a projected life expectancy of less than 1 year.
- Subject has an active systemic or cutaneous infection or inflammation (e.g.,
septicemia at the time of the procedure).
- Subject has systemic hypertension unresponsive to treatment (>180mmHg systolic and
>110mm diastolic).
- Subject has significant bleeding coagulopathy or platelet disorder, (INR> 2.0),
including known thrombocytopenia (platelet count <100,000/µL), thrombasthenia, Von
Willebrand's disease, Factor V deficiency, or anemia (hemoglobin <10 g/dL, or
hematocrit <30%).
- Subject presents with chronic renal insufficiency (creatinine ≥3.0mg/dl).
- Subject presents with hemodynamic instability or is in need of emergent surgery or
emergent procedure.
- Subject presents with ST elevation myocardial infarction.
- Subject presents with unstable angina or non-ST elevation myocardial infarction and
has troponin level > 3 X upper limit of normal. There must be at least one troponin
level drawn > 6 hours after onset of chest pain.
- Subject has received low molecular weight heparin < 8 hours before vascular access,
glycoprotein IIb/IIIa inhibitor < 24 hours before vascular access, unfractionated
heparin by infusion < 1 hour before vascular access, or parenteral heparin at
anticoagulant dose (as opposed to DVT prophylaxis)< 6 hours before vascular access.
- Subjects who are clinically obese, defined as BMI >40.
- Subject has received femoral artery Vessel Closure Implant (VCI) (suture or staple)
at the target access site.
- Subject has received femoral artery VCI (collagen/PEG/PGA) at the target access site
within 90 days of AXERA procedure.
- Subject is unable to routinely walk at least 20 feet without assistance (e.g.,
requires a walker or wheelchair to mobilize, is leg amputee or has known paralysis)
or unable to ambulate within 2 hours post procedure.
- Subject has had prior vascular surgery or vascular grafts at the target femoral
artery access site.
- Subject has had a previous target femoral artery complication from angiography (such
as pseudoaneurysm, Arteriovenous (AV) fistula, dissection), small CFA, abnormal,
absent or weak distal ipsilateral pulse, or presenting with clinically significant
peripheral vascular disease in the vicinity of the puncture.
- Subject has a high puncture (i.e. above the inferior reflection of the inferior
epigastric artery).
- Subject has antegrade puncture.
- Subject has a stent in the ipsilateral common femoral artery.
- Subject is currently participating in an investigational drug or another device study
that clinically interferes with the current study endpoints.
We found this trial at
17
sites
Medical Center of Central Georgia Navicent Health is a designated Level I Trauma Center and...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials